Summary of clinical results
Clinical parameter . | Study Entry . | 1 Year . | P . |
|---|---|---|---|
| Overall response rate, no./no. total (%) | NA | 14/20 (70) | |
| Complete response rate, no./no. total (%) | NA | 2/20 (10) | |
| Prednisone dose, median mg/d | 40 | 10 | < .001 |
| Discontinued prednisone, no./no total (%) | NA | 4/19 (21)* | |
| Prednisone reduction of at least 50%, no./no. total (%) | NA | 13/19 (68) | |
| No change, or higher dose, no./no. total (%) | NA | 6/19 (32) | |
| Cutaneous involvement, median % | |||
| Total body surface area | 42 | 20 | .02 |
| Sclerodermatous involvement | 35 | 20 | .19 |
| Lichenoid involvement | 19.5 | 3 | .17 |
| Rheumatologic involvement | |||
| VAS pain score, median | 4 | 1.5 | .02 |
| VAS fatigue score, median | 5 | 2 | .50 |
| Preston dynamometer, average left and right hand, lb | 62.5 | 71.5 | .13 |
| Oral involvement | |||
| Pathology score | 11.75 | 12.5 | .63 |
| Ocular involvement | |||
| Schirmer test, average left and right eye, mm | 1 | 3.75 | < .99 |
Clinical parameter . | Study Entry . | 1 Year . | P . |
|---|---|---|---|
| Overall response rate, no./no. total (%) | NA | 14/20 (70) | |
| Complete response rate, no./no. total (%) | NA | 2/20 (10) | |
| Prednisone dose, median mg/d | 40 | 10 | < .001 |
| Discontinued prednisone, no./no total (%) | NA | 4/19 (21)* | |
| Prednisone reduction of at least 50%, no./no. total (%) | NA | 13/19 (68) | |
| No change, or higher dose, no./no. total (%) | NA | 6/19 (32) | |
| Cutaneous involvement, median % | |||
| Total body surface area | 42 | 20 | .02 |
| Sclerodermatous involvement | 35 | 20 | .19 |
| Lichenoid involvement | 19.5 | 3 | .17 |
| Rheumatologic involvement | |||
| VAS pain score, median | 4 | 1.5 | .02 |
| VAS fatigue score, median | 5 | 2 | .50 |
| Preston dynamometer, average left and right hand, lb | 62.5 | 71.5 | .13 |
| Oral involvement | |||
| Pathology score | 11.75 | 12.5 | .63 |
| Ocular involvement | |||
| Schirmer test, average left and right eye, mm | 1 | 3.75 | < .99 |
VAS indicates visual analog scale.
One patient not using prednisone at study initiation and one patient with disease relapse are excluded.